Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma

Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience

“…This is the first case series on autoHSCT in Western patients with IVLBCL in the rituximab era. Although Western patients have been reported to differ from Asian patients with IVLBCL in terms of clinical patterns, 1,3,4 the outcome of our patient cohort with a 2-year PFS of 82% is in line with that of autoHSCT in Asian case series, 4,6,15 but compares well with the 2-year PFS of 56% after standard R-CHOP. 6 Of note, none of the patients autografted in first remission had disease recurrence in our series despite central nervous system involvement in four of them.…”

“…In detail, in the pre-rituximab era, two out of four 5 and five out of seven 4 autografted patients with IVLBCL were described to survive without relapse. After introduction of rituximab, seven out of seven 6 and six out of six 15 patients have been reported to remain alive and relapse-free after autoHSCT.…”

Intravascular large B-cell lymphoma: an elusive diagnosis with challenging management

“…3,4 Another retrospective analysis of 6 patients with IVBCL who were treated with 6 cycles of R-CHOP as induction therapy and consolidated with ASCT reported all patients to be alive and in complete remission after a median follow-up of 56 months. 9 Based on the retrospective case series data by Kato and colleagues and considering that more than 80% of the patients with IVBCL were in the high-risk International Prognostic Index group, ASCT in first remission might be a useful treatment option for durable remission; however, because the median age for the diagnosis of IVBCL is about 70 years, ASCT may not be a realistic option for all patients.…”

Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma

“…Rituximab monotherapy can be given in patients with poor functional status. Patients who received autologous hematopoietic stem cell transplantation (auto-HSCT) as consolidation have a prolonged survival rate with a three-year OS of 91%-100% [18]. CNS prophylaxis should be considered as CNS relapse and extravascular CNS dissemination has been commonly reported.…”